CoChat

Preclinical Potency and Safety Studies of an AAV2-Mediated Gene Therapy Vector for the Treatment of MERTK Associated Retinitis Pigmentosa

Open access
Conlon, Thomas J., Deng, Wen-Tao, Erger, Kirsten, Cossette, Travis, Pang, Ji-jing, Ryals, Renee, Clément, Nathalie, Cleaver, Brian, McDoom, Issam, Boye, Shannon E., Peden, Marc C., Sherwood, Mark B., Abernathy, Corinne R., Alkuraya, Fowzan S., Boye, Sanford L., Hauswirth, William W. · 2013 · Human Gene Therapy Clinical Development
Cited by 99

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Proof of concept for MERTK gene replacement therapy has been demonstrated using different viral vectors in the Royal College of Surgeon (RCS) rat, a well characterized model of recessive retinitis pigmentosa that contains a mutation in the Mertk gene. MERTK plays a key role in renewal of photoreceptor outer segments (OS) by phagocytosis of shed OS tips. Mutations in MERTK cause impaired phagocytic activity and accumulation of OS debris in the interphotoreceptor space that ultimately leads to photoreceptor cell death. In the present study, we conducted a series of preclinical potency and GLP-compliant safety evaluations of an adeno-associated virus type 2 (AAV2) vector expressing human MERTK cDNA driven by the retinal pigment epithelium–specific, VMD2 promoter. We demonstrate the potency of the vector in RCS rats by improved electroretinogram (ERG) responses in treated eyes compared with contralateral untreated controls. Toxicology and biodistribution studies were performed in Sprague–Dawley (SD) rats injected with two different doses of AAV vectors and buffer control. Delivery of vector in SD rats did not result in a change in ERG amplitudes of rod and cone responses relative to balanced salt solution control–injected eyes, indicating that administration of AAV vector did not adversely affect normal retinal function. In vivo fundoscopic analysis and postmortem retinal morphology of the vector-injected eyes were normal compared with controls. Evaluation of blood smears showed the lack of transformed cells in the treated eyes. All injected eyes and day 1 blood samples were positive for vector genomes, and all peripheral tissues were negative. Our results demonstrate the potency and safety of the AAV2-VMD2-hMERTK vector in animal models tested. A GMP vector has been manufactured and is presently in clinical trial. Conlon and colleagues report results from a series of preclinical potency and safety evaluations of an AAV2 vector expressing human mer proto-oncogene tyrosine kinase (MERTK) cDNA driven by a retinal pigment epithelium-specific VMD2 promoter (AAV2-VMD2-hMERTK). They demonstrate that a single injection of this vector is effective in a rat model of recessive retinitis pigmentosa, whereas biodistribution studies indicate that vector is not spread outside the eye.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/humc.2013.037

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 99

Metadata

Authors
Conlon, T. J., Deng, W.-T., Erger, K., Cossette, T., Pang, J.-J., Ryals, R., Clément, N., Cleaver, B., McDoom, I., Boye, S. E., Peden, M. C., Sherwood, M. B., Abernathy, C. R., Alkuraya, F. S., Boye, S. L., & Hauswirth, W. W.
Venue
Human Gene Therapy Clinical Development
Published
2013-03
Volume
24
Issue
1
Pages
23-28
ISSN
  • 2324-8637 (ISSN-L)
  • 2324-8645
OpenAlex
W2020418915
Cited by
99
References
7
FWCI
4.84
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preclinical Potency and Safety Studies of an AAV2-Mediated Gene Therapy Vector for the Treatment of MERTK Associated Retinitis Pigmentosa. https://app.cochat.ai/papers/10.1089/humc.2013.037
The paper
Conlon, T. J., Deng, W.-T., Erger, K., Cossette, T., Pang, J.-J., Ryals, R., Clément, N., Cleaver, B., McDoom, I., Boye, S. E., Peden, M. C., Sherwood, M. B., Abernathy, C. R., Alkuraya, F. S., Boye, S. L., & Hauswirth, W. W. (2013). Preclinical Potency and Safety Studies of an AAV2-Mediated Gene Therapy Vector for the Treatment of MERTK Associated Retinitis Pigmentosa. Human Gene Therapy Clinical Development. https://doi.org/10.1089/humc.2013.037

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.